Table 4. Post-transplant complications- adjusted cox proportional hazards.
| Covariate | 90-day survival | 1-year survival | 5-year survival | |||||
|---|---|---|---|---|---|---|---|---|
| HR, 95% CI | P value | HR, 95% CI | P value | HR, 95% CI | P value | |||
| Complication-free survival | ||||||||
| 2002−2015 cohort | ||||||||
| A1ATD (vs. COPD) | 1.30 (0.48−3.51) | 0.611 | 1.15 (0.54−2.48) | 0.714 | 0.89 (0.46−1.71) | 0.726 | ||
| Recipient age (per 10 years) | 1.01 (0.52−1.98) | 0.976 | 1.12 (0.63−1.99) | 0.693 | 1.27 (0.80−2.00) | 0.310 | ||
| Donor age (per 10 years) | 0.88 (0.66−1.18) | 0.407 | 0.90 (0.73−1.11) | 0.320 | 0.98 (0.84−1.15) | 0.847 | ||
| SLTx (vs. BLTx) | 0.43 (0.16−1.15) | 0.092 | 0.32 (0.15−0.69) | 0.004 | 0.44 (0.25−0.79) | 0.005 | ||
| Male (vs. female) | 1.78 (0.76−4.21) | 0.187 | 2.06 (1.09−3.87) | 0.025 | 1.40 (0.89−2.19) | 0.142 | ||
| LAS era (vs. pre-LAS) | 0.72 (0.24−2.17) | 0.553 | 0.64 (0.28−1.49) | 0.303 | 0.70 (0.39−1.23) | 0.210 | ||
| LAS cohort | ||||||||
| A1ATD (vs. COPD) | 1.50 (0.44−5.08) | 0.515 | 1.01 (0.32−3.16) | 0.991 | 1.03 (0.44−2.41) | 0.941 | ||
| Recipient age (per 10 years) | 0.86 (0.43−1.71) | 0.662 | 1.01 (0.50−2.01) | 0.988 | 0.94 (0.57−1.55) | 0.815 | ||
| Donor age (per 10 years) | 0.76 (0.54−1.08) | 0.122 | 0.76 (0.60−0.98) | 0.031 | 0.82 (0.69−0.99) | 0.035 | ||
| SLTx (vs. BLTx) | 0.67 (0.23−1.91) | 0.451 | 0.43 (0.19−0.99) | 0.048 | 0.52 (0.27−1.00) | 0.048 | ||
| Male (vs. female) | 3.27 (1.02−10.43) | 0.046 | 1.70 (0.95−3.05) | 0.072 | 1.70 (0.95−3.05) | 0.072 | ||
| GI complication-free survival | ||||||||
| 2002−2015 cohort | ||||||||
| A1ATD (vs. COPD) | 0.94 (0.24−3.67) | 0.925 | 0.88 (0.32−2.38) | 0.797 | 0.76 (0.36−1.60) | 0.464 | ||
| Recipient age (per 10 years) | 0.98 (0.42−2.27) | 0.963 | 1.23 (0.58−2.60) | 0.584 | 1.34 (0.77−2.31) | 0.300 | ||
| Donor age (per 10 years) | 0.83 (0.58−1.19) | 0.321 | 0.91 (0.71−1.16) | 0.433 | 0.97 (0.82−1.16) | 0.767 | ||
| SLTx (vs. BLTx) | 0.36 (0.11−1.21) | 0.098 | 0.34 (0.13−0.88) | 0.026 | 0.64 (0.34−1.23) | 0.185 | ||
| Male (vs. female) | 1.36 (0.50−3.74) | 0.548 | 1.87 (0.89−3.93) | 0.100 | 1.15 (0.71−1.86) | 0.577 | ||
| LAS era (vs. pre-LAS) | 0.69 (0.17−2.83) | 0.609 | 0.63 (0.22−1.78) | 0.380 | 0.77 (0.41−1.45) | 0.425 | ||
| LAS cohort | ||||||||
| A1ATD (vs. COPD) | 1.65 (0.36−7.62) | 0.519 | 1.14 (0.30−4.28) | 0.851 | 1.64 (0.71−3.82) | 0.249 | ||
| Recipient age (per 10 years) | 0.93 (0.35−2.47) | 0.890 | 1.38 (0.49−3.85) | 0.543 | 1.18 (0.63−2.21) | 0.601 | ||
| Donor age (per 10 years) | 0.63 (0.40−1.00) | 0.049 | 0.70 (0.52−0.93) | 0.016 | 0.74 (0.60−0.92) | 0.007 | ||
| SLTx (vs. BLTx) | 0.59 (0.17−2.06) | 0.407 | 0.41 (0.15−1.10) | 0.076 | 0.67 (0.33−1.34) | 0.259 | ||
| Male (vs. female) | 2.64 (0.65−10.65) | 0.172 | 1.50 (0.80−2.83) | 0.206 | 1.50 (0.80−2.83) | 0.206 | ||
| Airway complication-free survival | ||||||||
| 2002−2015 cohort | ||||||||
| A1ATD (vs. COPD) | 1.84 (0.42−8.02) | 0.419 | 1.48 (0.57−3.89) | 0.422 | 0.93 (0.47−1.84) | 0.841 | ||
| Recipient age (per 10 years) | 0.93 (0.39−2.21) | 0.874 | 1.46 (0.73−2.94) | 0.288 | 1.46 (0.87−2.46) | 0.151 | ||
| Donor age (per 10 years) | 1.11 (0.74−1.66) | 0.628 | 1.18 (0.90−1.56) | 0.225 | 1.15 (0.95−1.38) | 0.151 | ||
| SLTx (vs. BLTx) | 0.40 (0.10−1.65) | 0.205 | 0.30 (0.11−0.85) | 0.024 | 0.69 (0.36−1.31) | 0.253 | ||
| Male (vs. female) | 1.29 (0.35−4.73) | 0.702 | 2.32 (0.90−6.02) | 0.082 | 1.76 (1.03−3.00) | 0.038 | ||
| LAS era (vs. pre-LAS) | 0.41 (0.11−1.46) | 0.167 | 0.30 (0.12−0.80) | 0.016 | 0.55 (0.30−1.03) | 0.062 | ||
| LAS cohort | ||||||||
| A1ATD (vs. COPD) | 1.02 (0.12−8.69) | 0.982 | 0.46 (0.05−4.19) | 0.49 | 0.73 (0.29−1.87) | 0.516 | ||
| Recipient age (per 10 years) | 1.19 (0.45−3.17) | 0.726 | 2.05 (0.75−5.61) | 0.161 | 1.55 (0.83−2.92) | 0.172 | ||
| Donor age (per 10 years) | 0.92 (0.53−1.59) | 0.762 | 0.96 (0.69−1.33) | 0.817 | 0.91 (0.74−1.12) | 0.371 | ||
| SLTx (vs. BLTx) | 0.51 (0.08−3.11) | 0.464 | 0.40 (0.11−1.42) | 0.155 | 0.76 (0.36−1.61) | 0.473 | ||
| Male (vs. female) | 2.12 (0.33−13.48) | 0.425 | 2.65 (1.28−5.49) | 0.009 | 2.65 (1.28−5.49) | 0.009 | ||
HR, hazard ratio; A1ATD, alpha-1-antitrypsin deficiency; COPD, chronic obstructive pulmonary disease; SLTx, single lung transplant; BLTx, bilateral lung transplant; LAS, lung allocation score; GI, gastrointestinal.